Literature DB >> 19763076

Update on vaccine-derived polioviruses--worldwide, January 2008-June 2009.

.   

Abstract

In 1988, the World Health Assembly resolved to eradicate poliomyelitis worldwide. Subsequently, the Global Polio Eradication Initiative of the World Health Organization (WHO) reduced the global incidence of polio associated with wild polioviruses (WPVs) from an estimated 350,000 cases in 125 countries in 1988 to 1,651 reported cases in 2008 and reduced the number of countries that have never interrupted WPV transmission to four (Afghanistan, India, Nigeria, and Pakistan). Under current WHO plans, when the goal of eradicating all WPV transmission is attained, oral poliovirus vaccine (OPV) use worldwide eventually will be discontinued. However, because vaccine-derived polioviruses (VDPVs) can produce polio outbreaks in areas with low rates of Sabin OPV coverage and can replicate for years in immunodeficient persons, enhanced strategies are needed to limit emergence of VDPVs. This report updates previous summaries and describes VDPVs detected worldwide during January 2008-June 2009. During this period, 1) two new outbreaks of circulating VDPVs (cVDPVs) (accounting for 4-20 cases) were identified in the Democratic Republic of Congo and Ethiopia; 2) a previously identified outbreak in Nigeria ultimately resulted in a cumulative total of 292 cases; 3) two newly identified paralyzed immunodeficient persons in Argentina and the United States were found to excrete VDPVs; and 4) isolated VDPVs were found among persons and environmental samples in 11 countries. All countries need to maintain 1) high rates of poliovirus vaccination coverage to prevent VDPV spread and 2) sensitive poliovirus surveillance to detect VDPVs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19763076

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  21 in total

1.  Detection of imported wild polioviruses and of vaccine-derived polioviruses by environmental surveillance in Egypt.

Authors:  Soile Blomqvist; Laila El Bassioni; Eman M El Maamoon Nasr; Anja Paananen; Svetlana Kaijalainen; Humayun Asghar; Esther de Gourville; Merja Roivainen
Journal:  Appl Environ Microbiol       Date:  2012-05-11       Impact factor: 4.792

2.  Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor.

Authors:  Zhaochun Chen; Elizabeth R Fischer; Diana Kouiavskaia; Bryan T Hansen; Steven J Ludtke; Bella Bidzhieva; Michelle Makiya; Liane Agulto; Robert H Purcell; Konstantin Chumakov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

3.  Feasibility of quantitative environmental surveillance in poliovirus eradication strategies.

Authors:  W J Lodder; A M Buisman; S A Rutjes; J C Heijne; P F Teunis; A M de Roda Husman
Journal:  Appl Environ Microbiol       Date:  2012-03-23       Impact factor: 4.792

4.  Sabin and wild type polioviruses from children who presented with acute flaccid paralysis in Nigeria.

Authors:  A O Adedeji; I O Okonko; F D Adu
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927

5.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

6.  Mechanisms controlling virulence thresholds of mixed viral populations.

Authors:  Karen Z Lancaster; Julie K Pfeiffer
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

Review 7.  Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.

Authors:  Jean Guo; Sara Bolivar-Wagers; Nivedita Srinivas; Marisa Holubar; Yvonne Maldonado
Journal:  Vaccine       Date:  2015-01-16       Impact factor: 3.641

8.  Emergence and localized circulation of a vaccine-derived poliovirus in an isolated mountain community in Guangxi, China.

Authors:  Dongmei Yan; Li Li; Shuangli Zhu; Yong Zhang; Junjing An; Dongyan Wang; Ning Wen; Jaume Jorba; Wei Liu; Ge Zhong; Lin Huang; Olen Kew; Xiaofeng Liang; Wenbo Xu
Journal:  J Clin Microbiol       Date:  2010-07-14       Impact factor: 5.948

9.  Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria.

Authors:  Cara C Burns; Jing Shaw; Jaume Jorba; David Bukbuk; Festus Adu; Nicksy Gumede; Muhammed Ali Pate; Emmanuel Ade Abanida; Alex Gasasira; Jane Iber; Qi Chen; Annelet Vincent; Paul Chenoweth; Elizabeth Henderson; Kathleen Wannemuehler; Asif Naeem; Rifqiyah Nur Umami; Yorihiro Nishimura; Hiroyuki Shimizu; Marycelin Baba; Adekunle Adeniji; A J Williams; David R Kilpatrick; M Steven Oberste; Steven G Wassilak; Oyewale Tomori; Mark A Pallansch; Olen Kew
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

10.  Detection of vaccine-derived poliovirus circulation by environmental surveillance in the absence of clinical cases.

Authors:  John Kofi Odoom; Evangeline Obodai; Gifty Boateng; Stanley Diamenu; Keren Attiku; Patrick Avevor; Ewurabena Duker; Bismarck Boahene; Miriam Eshun; Emmanuel Gberbie; Joseph Kwadwo Larbi Opare
Journal:  Hum Vaccin Immunother       Date:  2021-01-30       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.